Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D

Abstract

This paper explores how changes in genetics, database, high-throughput screening and bioinformatics technologies have allowed pharmaceutical firms to exploit economies of scale in experimentation. Traditional craft-based, sequential experimentation in chemistry and biology has been complemented by firstly, the automated, mass-production analysis of populations and secondly, by 'in silico' experimentation using simulations and databases. The changes are analysed within a Chandlerian framework that highlights how increases in the 'throughput' of R&D are dependent on organizational and managerial responses to systemic uncertainty.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 144 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.